Best Options Strategy for ORIC
Looking for the best options strategy for ORIC Pharmaceuticals, Inc. (ORIC)? There is no single answer — the right play depends on your outlook, your risk tolerance and current implied volatility. Below, our free engine shows the highest-scoring defined-risk strategy on the live ORIC option chain right now, and a simple map from your view on ORIC to the strategy that fits it. Model any of them in the calculator before you trade.
About ORIC
ORIC Pharmaceuticals, Inc. (ORIC) is a major company in Biotechnology. Options traders on ORIC tend to watch , since these can drive large moves in the share price.
About ORIC Pharmaceuticals, Inc.
ORIC Pharmaceuticals is a clinical-stage biotech company focused on developing cancer treatments that target resistance mechanisms tumors use to evade existing therapies. The company's lead candidates are enozertinib, an orally available inhibitor designed to cross into the brain and block EGFR and HER2 mutations found in certain lung cancers, currently in early-stage clinical testing; and rinzimetostat, a different class of drug that works through the polycomb repressive complex 2 pathway and is being studied for prostate cancer. Both compounds remain in Phase 1b trials, where safety and early efficacy signals are being evaluated in patient populations.
ORIC generates its revenue potential through partnerships with established pharmaceutical companies. The company has agreements with Bayer and Johnson & Johnson to test rinzimetostat in combination with their respective hormone therapies for prostate cancer. These collaborations also provide supply arrangements, allowing ORIC to focus its resources on drug development while larger partners handle manufacturing and distribution logistics. Founded in 2014 and based in South San Francisco, the company remains pre-commercial, with no…
Today's top-scoring strategy for ORIC
Our engine ranks defined-risk strategies on the live ORIC chain by probability of profit and risk/reward, then surfaces the best-scoring one. It is an educational illustration, not advice.
| Action | Qty | Type | Strike | Premium |
|---|---|---|---|---|
| Buy | 1× | PUT | $7 | $1.49 |
| Sell | 1× | PUT | $12 | $4.58 |
| Sell | 1× | CALL | $11 | $1.40 |
| Buy | 1× | CALL | $15 | $0.16 |
Simulation
Forward simulation of 6,000 lognormal price paths to expiration — not a historical backtest.
Live scan from 2026-07-02 · quotes delayed ~15 minutes
Implied volatility
ORIC is currently trading with high implied volatility, which makes its options expensive — and attractive to sell. On the options we scanned that was around 264% implied volatility, and higher implied volatility means richer premiums and wider expected moves.
Options on ORIC currently price in about 264% implied volatility, versus roughly 77% the stock has actually realised over the past month. That makes options relatively expensive — an edge for strategies that sell premium, such as credit spreads and iron condors.
Off that volatility, the options market is pricing a move of about ±$5.93 (±52%) in ORIC by 2026-07-17 — a range of roughly $5.44 to $17.3. Strikes inside that band hold most of the premium and see most of the action.
Key figures
- Market cap
- $1.2B
- Beta (vs market)
- 1.06
- 52-week range
- $7.23–$14.93 (54% up the range)
- Short interest
- 20.6% of float · 12.4 days to cover
With 20.6% of ORIC's float sold short, squeeze and gap risk are elevated — one reason its options can stay expensive.
How to choose an options strategy for ORIC
Start with your outlook on ORIC, then match it to a defined-risk structure. Here are the most common choices and when each makes sense:
Bullish
Buy a call for leverage with capped risk, or a bull call spread to lower the cost and breakeven when you have a target price.
Long Call → Bull Call Spread →Bearish
Buy a put to profit from a decline with defined risk, or a bear put spread to cheapen the trade when you expect a measured move down.
Long Put → Bear Put Spread →Neutral
Sell an iron condor to collect premium while ORIC stays between two strikes, or write a covered call against shares you already own.
Iron Condor → Covered Call →How we pick the best strategy
For each ticker we pull the live option chain, build every supported strategy around the at-the-money strikes, and score them on probability of profit, risk/reward and capital efficiency — favouring defined-risk structures where the maximum loss is known up front. Methodology →
Open ORIC in the free calculator →
Frequently asked questions
What is the best options strategy for ORIC?
It depends on your outlook. Bullish traders often use a long call or bull call spread on ORIC; bearish traders a long put or bear put spread; neutral traders an iron condor or covered call. Our live scan above shows the current highest-scoring defined-risk play.
Are ORIC options liquid enough to trade?
ORIC Pharmaceuticals, Inc. (ORIC) is among the most actively-traded US options, which usually means tight bid/ask spreads and plenty of strikes and expirations — though you should always check the open interest and spread on the exact contract.
How much money do I need to trade ORIC options?
Buying a single ORIC call or put can cost as little as the premium (often one to a few hundred dollars), while income strategies like a cash-secured put need enough capital to buy 100 shares if assigned.
Is this financial advice?
No. Everything here is educational and uses delayed, third-party data. It is not a recommendation to trade ORIC or any security. Do your own research.
What does ORIC Pharmaceuticals, Inc. do?
ORIC Pharmaceuticals, Inc. (ORIC) operates in the Biotechnology industry. The "About ORIC Pharmaceuticals, Inc." section above gives a fuller picture of what the company does and how it earns money.
Does ORIC Pharmaceuticals, Inc. pay a dividend?
ORIC Pharmaceuticals, Inc. does not currently pay a dividend, so there is no ex-dividend assignment risk to plan around for options strategies.
Tickers related to ORIC
Comparing ORIC with similar names can help you choose the best options strategy:
Company information
- Headquarters
- 240 E. Grand Ave, 2nd Floor, South San Francisco, CA, 94080, United States
- Industry
- Biotechnology
- Employees
- 104
- CEO
- Dr. Jacob M. Chacko M.B.A., M.D.
- Phone
- 650 388 5600
- Website
- www.oricpharma.com
Best Options Strategy by Ticker →
Educational use only. Quotes are delayed ~15 minutes and nothing here is financial advice. Options trading involves substantial risk of loss. Privacy · Terms.